Premium Ad Formats

Showing 3788 articles
Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

Zegna Charts Steady Course Amid Leadership Shift and China Volatility, Fueled by DTC Momentum

The Ermenegildo Zegna Group reported a resilient 2025, with full-year revenues reaching €1.92 billion. A strong fourth-quarter acceleration, driven by a 10% surge in direct-to-consumer sales, underscores the luxury group's strategic pivot away from wholesale. While the Americas and EMEA regions showed robust growth, Greater China remains a volatile market as the company navigates a planned leadership transition and industry headwinds.